Aloret

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aloret

This section provides a foundational overview of the medicinal entity Aloret, focusing on its composition, classification, and general function, while strictly excluding details on dosage, specific therapeutic indications, or safety information.

Property Description
Active ingredient Desloratadine
Form Oral dosage forms (Tablet, Oral Solution)
Pharmacological class Second-Generation H₁ Antihistamine
Common use General antiallergic agent
Origin Synthetic, Active Metabolite of Loratadine

What is Aloret and Its Active Ingredient?

The medicine sold under the name Aloret is an antiallergic agent that contains the active substance Desloratadine. Desloratadine is a synthetic compound and a single-ingredient product (monotherapy), chemically identified as the major active metabolite of Loratadine. This means the drug is already in its fully active form, providing a consistent and predictable systemic action without requiring complex metabolism upon absorption. The pharmaceutical preparation combines the Desloratadine with standard excipients necessary for its final solid or liquid oral dosage forms.

Classification: Second-Generation H₁ Antihistamine

Aloret is classified as a second-generation H₁ antihistamine, functioning as a selective peripheral H₁ receptor antagonist. This drug acts by targeting and blocking the effects of histamine, a chemical released by the body that causes allergic symptoms. A comprehensive review of the drug's action confirms its key feature: its structure allows for minimal penetration of the blood-brain barrier, which is the basis for its distinction as a non-sedating agent. This non-drowsy property is a core differentiating factor, widely clinically recognized for allowing relief of symptoms without impacting the patient's ability to maintain alertness.

General Purpose and Available Forms

The primary general purpose of Desloratadine is to block the histamine pathway, providing a supportive, systemic way to help relieve the overall physical manifestations of the allergic response. The medicine is supplied for the oral route of administration and is available in common oral dosage forms, including the film-coated tablet and an oral solution. Desloratadine is intended for systemic use in managing allergic conditions. The availability of the oral solution specifically allows Aloret to target patient groups, such as children, who may require a liquid formulation for precise dosing and easier administration.

What side effects are possible with Aloret?

Possible Side Effects and Safety Information

The officially documented safety profile for Aloret is structured by government regulatory authorities to detail adverse reactions by the body system affected (System-Organ-Class) and their statistical likelihood (Frequency Classification).

Commonly Documented Adverse Reactions

Adverse reactions that are classified in regulatory documents as Very Common or Common include effects across several System-Organ Classes. For instance, Nervous System Disorders may involve headache and somnolence (drowsiness). Gastrointestinal disorders commonly reported are typically mild, but the full safety document lists all reactions based on their official frequency bands derived from clinical data and post-marketing surveillance.

Serious Adverse Reactions and Contraindications

The regulatory labels specify certain safety risks based on their potential clinical severity. Serious adverse reactions, while reported at lower frequencies, are formally classified for continuous safety monitoring (e.g., life-threatening events or those requiring hospitalization).

Mandatory safety restrictions and contraindications are established for specific circumstances and populations. For example, Aloret is contraindicated in patients with known hypersensitivity to the active substance, loratadine, desloratadine, or any of its excipients. Caution is generally required for patients with severe liver impairment or kidney impairment as these conditions may affect the body's ability to process the medication.

Population-Specific and Exposure-Related Notes

  • Pregnancy and Breastfeeding: The official labeling typically states that use of Aloret is generally not recommended during pregnancy or while breastfeeding, unless the potential benefits outweigh the possible risks, as the active substance passes into breast milk.
  • Exposure Patterns: Some documented adverse effects, such as flu-like symptoms, may be noted in regulatory sources as being most prominent at the initiation of therapy and potentially decreasing with continued treatment, which helps structure the understanding of risk over the course of use.

This information represents the explicit safety structure defined in authoritative regulatory documents, providing an objective description of the medicine's risk profile.

Overdose and Emergency Response

The official regulatory documents state that the adverse event profile associated with an overdose of Aloret (Desloratadine) is similar to that seen with therapeutic doses, but the resulting effects occur with a higher magnitude. Documented clinical manifestations of overdose exposure include neurological effects such as somnolence and headache, alongside cardiovascular signs like tachycardia (fast heart rate) and palpitations.

Serious systemic outcomes reported in post-marketing surveillance include seizures and signs of hepatotoxicity, such as hepatitis and elevations of liver enzymes. In the event of a suspected or confirmed overdose, regulatory guidance mandates that immediate medical attention must be sought. Emergency services must be contacted if the victim has collapsed, experiences trouble breathing, or cannot be awakened.

The regulatory labels outline that treatment should focus on symptomatic and supportive treatment, with the consideration of standard measures to remove unabsorbed active substance. No specific antidote is known. The drug is documented to be not eliminated by haemodialysis, and its removal by peritoneal dialysis is not established in official regulatory documents.

Therapeutic Uses of Aloret

What Aloret treats: main uses and benefits

Aloret belongs to a class of medications known as retinoids. It is primarily utilized in the management of severe skin conditions that have not responded to standard treatments. By influencing cell growth and maturation, the medication helps to normalize the skin's development process.

Main Uses

The most common application for Aloret is the treatment of severe, recalcitrant nodular acne. This form of acne is characterized by inflammatory lesions that are often painful and deep-seated. It is typically reserved for cases where other therapies, such as systemic antibiotics or topical treatments, have proven ineffective.

Additionally, Aloret may be indicated for other keratinization disorders. These conditions involve the abnormal development of the skin's outer layer and can include:

  • Psoriasis: Specifically severe or generalized forms that cover large areas of the body.
  • Ichthyosis: A group of genetic skin disorders characterized by dry, thickened, and scaly skin.
  • Darier’s disease: A rare condition that causes crusty patches on the skin.

Benefits and Mechanisms of Action

Aloret works at a cellular level to provide several key benefits for the skin:

  • Reduction of Sebum Production: It significantly decreases the size and activity of the sebaceous (oil) glands, which reduces the amount of oil produced by the skin.
  • Prevention of Clogged Pores: The medication helps prevent the formation of comedones (blackheads and whiteheads) by ensuring skin cells shed properly rather than blocking pores.
  • Anti-inflammatory Effects: It helps reduce the redness and swelling associated with severe inflammatory skin conditions.
  • Long-term Remission: For many patients with severe acne, a complete course of treatment can lead to prolonged clearance of the skin, even after the medication is discontinued.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

This section details the official population eligibility and non-eligibility for Aloret (Desloratadine), based strictly on government regulatory documentation. No dosing or therapeutic claims are included.

Eligibility Status by Population

Category Regulatory Status & Condition
Eligible Age Groups Adults and adolescents 12 years of age and older (tablets/solution); Children over 1 year (oral solution, may vary by region)
Contraindications (Must Not Use) Patients with known hypersensitivity to desloratadine, loratadine, or any of the product's excipients.
Conditional Use/Restrictions Use with caution in patients with severe renal insufficiency or hepatic impairment (often requiring dosing adjustments).
Physiological Status Pregnancy and Lactation are generally not recommended due to safety not being established or unknown effects on the infant.

Additional Eligibility Limitations

Official labeling identifies specific conditions and age groups with limited or conditional eligibility:

  • Pediatric Limitations: The safety and efficacy of tablets in children below 12 years of age have not been established. The oral solution is not established for use in infants below 1 year of age (or 6 months in some jurisdictions).
  • Hereditary Disorders: Patients with certain hereditary sugar intolerances (e.g., total lactase deficiency for the tablet form) are contraindicated due to formulation excipients.
  • Seizure Risk: The medicine should be administered with caution in patients, particularly young children, with a medical or familial history of seizures.

Connection to the overall eligibility profile

Regulatory authorities define the scope of use by designating specific populations as contraindicated (mandatory exclusion), outlining conditions that require caution (restricted use, such as severe renal impairment), and citing a lack of established safety data for certain age groups (use not established in infants and younger children).

What should I know about interactions with other medicines?

The official interaction profile for Aloret is primarily defined by pharmacokinetic interactions that result in increased systemic exposure to the active compound. Co-administration with inhibitors, including the azole antifungal ketoconazole and the macrolide antibiotic erythromycin, formally results in documented increased plasma concentrations and overall exposure of desloratadine and its active metabolite. Similar increases in systemic exposure are officially noted when the medicine is co-administered with cimetidine and fluoxetine. Clinical trials supporting these findings formally stated that no clinically relevant changes in the established safety profile were observed when desloratadine was taken with ketoconazole or erythromycin.

A specific restriction is documented: Aloret is formally contraindicated in patients with a known hypersensitivity to the drug's components or to its parent drug, loratadine. Caution is advised regarding the co-administration of alcohol, based on post-marketing reports of alcohol intolerance and intoxication, despite clinical studies showing no potentiation of performance-impairing effects. Furthermore, patients with severe renal impairment or hepatic impairment exhibit significantly increased systemic exposure to the drug, representing a population-dependent interaction constraint. The regulatory documents state that the drug's absorption is not affected by food.

Mechanism of Action

Aloret (Desloratadine) is a second-generation antihistamine that acts through multiple, interconnected mechanisms to influence physiological processes mediated by immune factors.

Targeted Histamine H1 Receptor Antagonism

Aloret's primary mechanistic domain involves its highly selective antagonism of peripheral Histamine H1 receptors. By blocking these key receptors on various cell surfaces, the drug prevents the binding and action of endogenous histamine, a major mediator released during activation of immune response pathways. This action is critical for modifying early molecular steps and altering signaling sequences within pathways that rely on histamine function.

Modulation of Inflammatory Signaling Cascades

The drug engages mechanisms that influence feedback regulation within inflammatory pathways, in addition to H1 blockade. Aloret has been shown to suppress downstream signaling sequences, such as the NF-kappa B and ERK1/2 pathways. This inhibitory effect modifies a range of molecular steps, influencing the level of released mediators and the resulting physiological response profile in systems where specific transmitters dominate.

Influence on Chemokine and Cytokine Release

Aloret affects processes driven by distinct signaling patterns by directly altering the release of inflammatory chemicals. It influences the production of various chemokines and cytokines (like IL-8 and RANTES) from immune cells. This influence affects the migration of inflammatory cells to affected tissues, resulting in an alteration of the physiological response profile.

Dosage and Administration Information

How to Use Aloret: Administration Guidelines

The following instructions detail the use of Aloret, covering administration and dosing rules.

Administration Protocol

Instruction Entity Administration Instruction
Route of Administration Oral (swallowed by mouth).
Timing in Relation to Meals May be taken without regard to meals (with or without food).
Frequency Once Daily (QD). Do not exceed the maximum daily dose.
Missed Dose Rule Take the missed dose upon remembering. If close to the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose.

Dosing Rules

Population Group Standard Dose
Adults and Adolescents (12+ years) 10 mg once daily.
Children (6–11 years) 10 mg once daily (or 5 mg depending on specific formulation).
Children (2–5 years) 5 mg (e.g., 5 mL of a 1 mg/ mL solution) once daily.

Special Procedural Conditions

Patients should use a calibrated measuring device, such as a dosing syringe or spoon, when administering the Oral Syrup or Solution to ensure accuracy. If using an Orally Disintegrating Tablet (ODT), handle with dry hands, place it on the tongue, and allow it to dissolve completely before swallowing; water is not required. Patients with severe hepatic or renal impairment follow specific protocols for dose adjustment, which may involve taking the recommended 10 mg dose every other day instead of daily to accommodate reduced drug clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aloret (Desloratadine)

This section provides an overview of the key clinical research that has explored the substance desloratadine, strictly focusing on the evidence landscape as documented in official and peer-reviewed sources.

Evidence for Use in Allergic Rhinitis

The primary body of research for Aloret was evaluated in short-term, randomized controlled trials (RCTs) exploring allergic rhinitis, a condition characterized by fluctuating or episodic symptoms like sneezing and runny nose. Studies were applied in research contexts involving unstable symptoms, examining outcomes related to physical discomfort and daily functioning. The findings describe patterns observed in the studies where participants reported changes in certain symptoms. The results apply only to the populations studied, and direct, comparative evidence against every other available therapy is often lacking.

Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

Aloret was evaluated in studies focusing on chronic hives, a condition involving periods of heightened symptoms such as persistent itching and recurring welts. Research monitored patient-reported outcomes describing perceived discomfort. The evidence was associated with changes measured during the study period, and research describes patterns related to symptom intensity over defined time intervals. However, for some aspects of chronic hives, findings were mixed, and certainty regarding long-term management remains lower than for the immediate, short-term data.

Research into Durability and Long-Term Follow-up

Most primary regulatory research involves time-limited trials, and therefore, long-term effects are not fully established. Research explored the product in observational settings beyond the typical short, defined trial periods. Data are still emerging regarding the durability of the measured changes, and there is limited information for long-term outcomes that would be considered definitive.

Studies in Specific Patient Populations and Limitations

The evidence for Aloret was evaluated in studies of children and adolescents experiencing allergy symptoms. While research describes patterns in these populations, data for certain groups, such as older adults, remain insufficient. The existing evidence highlights what is known and what is still uncertain. Clinical trials often had modest sample sizes, and comparative evidence against all other existing treatments is lacking. Because results apply only to the populations studied, research does not determine whether an individual will respond similarly.

Key Studies & References

  1. The Efficacy and Safety of High Dose (10 mg) of Desloratadine in the Treatment of Chronic Spontaneous Urticaria

Frequently Asked Questions (FAQ)

Common questions about Aloret (FAQ)


Q: How quickly do people typically start to notice the effect of Aloret?

Official studies indicate that the antihistaminic effects begin working within one hour of taking a dose. Patient-reported improvement in common symptoms, such as sneezing and runny nose, has been described as being observed as early as one day after starting treatment. This information is based on regulatory reviews of the drug’s performance.


Q: How long does the effect of a dose of Aloret usually last?

According to official product information, the antihistaminic effect of a single dose is described as persisting for up to 24 hours. This duration is consistent with the standard once-daily dosing frequency outlined in the administration guidelines.


Q: Can Aloret be taken alongside common over-the-counter pain relievers?

The official interaction profile primarily highlights specific prescription drugs that affect how Aloret is processed by the body. Regulatory reviews indicate there are no documented interactions with commonly used over-the-counter pain relievers, such as ibuprofen or acetaminophen.


Q: What is the main difference between Aloret and other drugs for the same condition?

Aloret is classified as a second-generation H₁ antihistamine. Official documents state that its chemical structure limits its ability to enter the central nervous system, which is the basis for its distinction as a non-sedating agent. This feature is a key differentiator from some older antihistamine products.


Q: What is the maximum number of days or weeks Aloret is typically prescribed for?

Official guidelines describe the duration of treatment as being linked to the type of allergic condition being addressed. For symptoms of intermittent allergic rhinitis, treatment may be discontinued once symptoms are resolved. For persistent allergic rhinitis, continued treatment may be advised during the entire period of allergen exposure.


Q: What are the common signs of an overdose of Aloret?

The official label instructs contacting a Poison Control Center or seeking medical help immediately in the event of a suspected overdose. In clinical studies, even high doses did not cause significant changes to heart rhythm. However, high doses of antihistamines have been generally associated with effects such as dizziness or loss of coordination.


Q: Is Aloret considered a new type of medicine?

The active substance in Aloret, desloratadine, is classified as a second-generation H₁ antihistamine. Records show that this medication was initially approved for use in allergic conditions in the early 2000s, positioning it within a more recently developed class of antihistamines.


Q: Can elderly patients use Aloret according to official documents?

Regulatory documents confirm that studies have included patients 65 years of age and older. Official guidance recommends caution for older adults due to the higher likelihood of decreased kidney or liver function. Reduced organ function may affect how the body processes the medication, which may lead to a requirement for a dose adjustment according to regulatory guidance.


Q: Is Aloret a drug that is easy to stop taking?

Official documentation does not suggest a specific risk of dependence or formal withdrawal with Aloret. However, general pharmacological data for the antihistamine class notes that abruptly stopping long-term use has sometimes been associated with temporary effects like activation or insomnia.


Q: What should I do if I think I might have missed a dose?

The official administration rule describes taking the missed dose upon remembering. If that time is very close to the next scheduled dose, the regulatory instruction is to skip the missed dose entirely and resume the regular schedule. Official guidelines prohibit taking a double dose to compensate for a missed one.


Q: Does taking Aloret affect your mood or mental focus?

Clinical studies generally show that the recommended dose does not impair psychomotor performance or mental focus. However, some post-marketing surveillance reports have led regulatory bodies to consider depressed mood as a potential, though rare, adverse reaction.


Q: What are the general rules for stopping Aloret safely?

For short-term conditions like intermittent allergic rhinitis, regulatory guidelines state that the treatment can be discontinued once symptoms have resolved. For drugs used chronically in the antihistamine class, the general medical approach described in pharmacological data is often cautious to minimize the chance of temporary discontinuation effects.


Q: Does Aloret affect sleep patterns?

While somnolence (drowsiness) is included as a commonly documented side effect on the regulatory label, official clinical studies on the product at the recommended dose indicate no adverse effects on objective measures of daytime sleepiness or sleep latency.


Q: Do studies suggest Aloret works better for some patient demographics than others?

Research evidence supports the drug's efficacy across the diverse populations studied, including children, adolescents, and adults. Official labeling notes that the drug is processed more slowly in a small percentage of people classified as 'poor metabolizers,' which may result in higher systemic exposure for those individuals.


Q: Can Aloret be crushed, split, or chewed?

The official administration method depends on the form. Regulatory guidance describes that film-coated tablets should be swallowed whole with water. Orally Disintegrating Tablets (ODTs) are designed to dissolve on the tongue. Official instructions indicate that these forms should not be crushed or chewed.


Q: How does taking Aloret change daily life activities?

Official regulatory reviews based on clinical trials have determined that the drug is suitable for those involved in skilled activities like driving or operating machinery. This determination is based on the finding that the drug, at its recommended dose, does not typically impair psychomotor performance or alertness.

How should Aloret be stored and disposed of?

How to Store and Dispose of Aloret

Official labeling defines strict storage conditions to maintain the stability of Aloret (Desloratadine) and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 25 C (77 F); do not store above 30 C.
Protection Keep the medicine in its original container and tightly closed to protect it from moisture and excess heat.
Safety Must be stored out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Instructions

Unused or expired Aloret must be disposed of according to official regulatory guidelines. Disposal must be done in accordance with local requirements, such as authorized drug take-back programs. Medicines should generally not be disposed of via wastewater or flushed down the toilet unless the official product labeling specifically instructs it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aloret found in:

A-Z Index: